IBS Patients Harbor Twice as Many Gut Bacteria as Healthy People, Study Finds

Irritable bowel syndrome affects roughly 10 to 15 percent of people worldwide, yet the specific bacteria taking up residence in affected guts remain poorly characterized in many regions. A new study by ZF Dakhil, KHA Aljasimee, and MJ Nasser, published in the Universal Publication Index e-Library, offers a closer look at that bacterial landscape, and the picture is striking: IBS patients carried more than twice as many bacterial isolates as healthy controls, with harmful species filling the space left by depleted beneficial microbes. The findings are preliminary and come from a single cohort, but they add concrete bacteriological detail to a field still working to define what a dysbiotic IBS gut actually looks like.

E. coli and K. pneumoniae Dominate the IBS Bacterial Profile

The researchers collected stool specimens from 80 IBS patients diagnosed using Rome IV criteria, the current clinical gold standard, and from 40 age- and sex-matched healthy individuals. Using traditional bacteriological cultures confirmed by 16S RNA gene sequencing, they catalogued every isolate. The IBS group yielded 248 bacterial isolates in total; the healthy control group produced just 98.

The most frequently identified species in IBS patients was Escherichia coli, accounting for 31.5 percent of all isolates. Klebsiella pneumoniae came second at 18.1 percent, followed by Enterococcus faecalis at 14.1 percent and Bacteroides fragilis at 11.3 percent. Lactobacilli (9.3 percent) and bifidobacteria (7.7 percent) were present but significantly reduced compared to healthy controls, a difference the authors report as statistically significant at p less than 0.01. That pattern, opportunistic and pathogenic species ascending while beneficial commensals decline, fits the broader concept of gut dysbiosis that researchers have associated with IBS symptoms, though the precise contribution of altered intestinal microbiota to IBS remains an active area of debate.

Why Antibiotic Resistance in IBS Matters for Treatment

Beyond species identification, the study tested antibiotic susceptibility using the Kirby-Bauer disk diffusion method according to CLSI criteria. The results raise a practical concern: Enterobacteriaceae isolated from IBS patients showed significant resistance to ampicillin (58.4 percent of isolates) and tetracycline (47.6 percent). Both are drugs sometimes used empirically for gastrointestinal complaints.

For a condition as prevalent as IBS, that resistance profile has real implications. The global burden of irritable bowel syndrome already strains healthcare systems through direct costs and lost productivity; if clinicians treating IBS-associated bacterial overgrowth reach for drugs that no longer work against the dominant strains, that burden deepens. The resistance rates documented here are not outliers in the broader antimicrobial resistance landscape, but their presence in a common functional GI disorder underscores why bacteriological profiling matters even when IBS is not typically treated as an infectious disease.

How the Team Combined Culture Methods with Gene Sequencing

One methodological strength of the study is its dual-track identification approach. Traditional culture methods are inexpensive and widely available but can miss low-abundance or fastidious species. The team addressed that limitation by confirming species identifications with 16S RNA gene sequencing, which can detect organisms that do not grow well under standard laboratory conditions. The combination improves confidence in the species-level assignments reported.

That said, 16S sequencing has its own ceiling. It identifies bacteria by a conserved genetic region rather than whole-genome analysis, which can blur species boundaries in some genera. Broader approaches, including shotgun metagenomics and multi-omics platforms, offer finer resolution and can also characterize functional genes, including those encoding antibiotic resistance enzymes. The current study does not use those methods, which is a limitation worth noting when interpreting the resistance data.

Open Questions About Geography, Sample Size, and Causality

The authors themselves flag a key gap: comprehensive bacteriological profiling of IBS stool specimens is lacking in certain geographic regions, and this study appears to address one such gap. That context matters for how far its findings generalize. A cohort of 80 patients and 40 controls, while adequately powered for the primary comparisons, is modest by the standards of large microbiome studies. It is also unclear from the available data how IBS subtype (diarrhea-predominant, constipation-predominant, or mixed) maps onto the bacterial profiles observed.

Causality is the deeper unresolved question. Does the bacterial imbalance documented here drive IBS symptoms, or does the gut environment created by IBS allow opportunistic species to proliferate? Reviews examining gut microbiota dysregulation in IBS consistently note that no single microbial signature reliably defines the condition, and directionality remains genuinely uncertain. This study adds a data point; it does not settle the debate.

Microbiota-Targeted Therapies Could Follow From This Kind of Profiling

If specific bacterial species can be reliably linked to IBS in defined populations, that opens a path toward more targeted interventions. Current microbiota-targeted IBS therapies range from probiotics and dietary modification to the antibiotic rifaximin and fecal microbiota transplantation, each with varying levels of evidence. Knowing which pathogens dominate, and which antibiotics they resist, could inform more rational antibiotic choices or help clinicians select probiotic strains aimed at restoring the lactobacilli and bifidobacteria this study found depleted.

For now, the work by Dakhil and colleagues represents a useful, if early, contribution to regional bacteriological profiling of IBS. Larger, multi-site studies using whole-metagenome approaches and IBS subtype stratification will be needed to confirm whether the species ratios reported here hold across populations and to build the causal evidence that could eventually change clinical practice.

Evidence rating

INVESTIGATIONAL — 76/100

Caveats:

• Observational design: this study identifies associations between bacterial profiles and IBS, but cannot establish that the bacterial imbalance causes IBS.
• Relatively small sample (80 IBS patients, 40 controls) from a single geographic location, limiting generalizability.
• Funding source was not disclosed by the authors.
• Published in a low-visibility journal; independent replication in larger cohorts is needed before clinical conclusions can be drawn.

Cross-sectional case-control study (80 IBS patients, 40 healthy controls) using 16S rRNA gene sequencing to characterize stool bacterial profiles. The study demonstrates an association between IBS and dysbiosis but cannot establish causation, and findings have not yet been independently replicated in a separate cohort.